{"entity":{"id":"juergen-wolf","kind":"person","name":"Jürgen Wolf","aka":[],"tldr":"Built the Network Genomic Medicine that brought molecular testing to lung cancer patients across Germany, and led the capmatinib GEOMETRY trial.","summary":"Jürgen Wolf is Medical Director of the Lung Cancer Group Cologne and Head of Network Genomic Medicine at Uniklinik Köln (CIO). His specialisms are lung cancer, molecular diagnostics networks and MET- and KRAS-targeted therapy, using comprehensive genomic profiling. He founded Network Genomic Medicine, which brought molecular testing to lung cancer patients across Germany by sequencing non-small-cell lung cancer across hundreds of centres. He was principal investigator of GEOMETRY mono-1, the New England Journal of Medicine trial of capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wolf%20J%5BAuthor%5D%20capmatinib"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["cgp"],"targets":["met"],"drugs":["capmatinib-tepotinib"],"companies":[],"institutions":["uniklinik-koeln"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Director, Lung Cancer Group Cologne; Head of Network Genomic Medicine","institutionId":"uniklinik-koeln","specialisms":["Lung cancer","Molecular diagnostics networks","MET and KRAS-targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wolf%20J%5BAuthor%5D%20capmatinib"}],"papers":[{"title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer (GEOMETRY mono-1)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2002787"},{"title":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2307980","doi":"10.1056/NEJMoa2307980"}]},"route":"/people/juergen-wolf/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"}],"target":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"drug":[{"id":"capmatinib-tepotinib","kind":"drug","name":"Capmatinib & tepotinib","route":"/drugs/capmatinib-tepotinib/"}],"institution":[{"id":"nngm","kind":"institution","name":"nationales Netzwerk Genomische Medizin Lungenkrebs","route":"/institutions/nngm/"},{"id":"uniklinik-koeln","kind":"institution","name":"Uniklinik Köln (CIO)","route":"/institutions/uniklinik-koeln/"}],"paper":[{"id":"paper-dellphi-301-nejm-2023","kind":"paper","name":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","route":"/key-papers/paper-dellphi-301-nejm-2023/"},{"id":"paper-ascend-4-lancet-2017","kind":"paper","name":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","route":"/key-papers/paper-ascend-4-lancet-2017/"}],"trial":[{"id":"nct01828099","kind":"trial","name":"ASCEND-4","route":"/trials/nct01828099/"}]}}